To develop our approach, we selected monoclonal antibodies currently studied for the development of AML immunotherapies: clone 4G8 (FLT3)16,32, Fab-79D (KIT)15,33 and 7G3 (CD123)34,35. This evidence concerns the gene IL3RA and acute myeloid leukemia.